leisure time -WSS

leisure time

author：focus 2025-09-29 23:12:22 - browse：23

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Test for long Covid? Researchers find new clue in blood samples

WSS

Physician groups backed by private equity giant lobby on mergers

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Lawsuit alleges UnitedHealth Group unit illegally denied claims

EQRx, failed developer of low

Dewpoint Therapeutics lays off staff after losing partnerships

My yearlong odyssey to get my son’s ADHD medication covered

hotspot

leisure time

knowledge

Moonlake's readout produced a cash windfall. Risks remain

AI generated plenty of interest at JPM but not a lot of trust

Medical leaders decry Supreme Court decision on affirmative action

Vertex non

Cancer drug shortages should be causing more outrage

New safety details link Apellis eye drug to rare cases of blindness

Malaria cases in Florida and Texas: Here’s what you need to know

New safety details link Apellis eye drug to rare cases of blindness

Activists slam private health insurers over coverage restrictions

Eli Lilly, Pfizer, and others want in on the online prescription market

explore

No plane should take off without an EpiPen onboard

Test for long Covid? Researchers find new clue in blood samples

Adults seen as increasingly susceptible to measles

Dewpoint Therapeutics lays off staff after losing partnerships

Trump indictment: Who are the 'co

What to expect as Trump is arraigned on his Jan 6. indictment

leisure time

leisure time

explore

focus